Phase 2 Study of Dabrafenib Plus Trametinib in Patients With BRAF V600E-Mutant Metastatic NSCLC: Updated 5-Year Survival Rates and Genomic Analysis

Authors: David Planchard, Benjamin Besse, Harry J.M. Groen, Sayed M.S. Hashemi, Julien Mazières, Tae Min Kim, Élisabeth Quoix, Pierre‐Jean Souquet, Fabrice Barlési, Christina S. Baik, Liza C. Villaruz, Ronan J. Kelly, Shirong Zhang, Monique Tan, Eduard Gasal, Libero Santarpia, Bruce E. Johnson - Journal of Thoracic Oncology 2021 cited by 269